Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults

Oncology

Volumn 58, Issue 2, 2000, Pages 108-116

  Nakamura, Mitsutoshi ^a,b   Konishi, Noboru ^b   Tsunoda, Shigeru ^a   Nakase, Hiroyuki ^a   Tsuzuki, Toshihide ^a   Aoki, Hideo ^a   Sakitani, Hiroyuki ^a   Inui, Takuo ^a   Sakaki, Toshisuke ^a  

^a Department of Neurosurgery ^*  (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Astrocytoma, low grade; p53; Prognosis; Radiation; Radical surgery; Survival

Indexed keywords

PROTEIN P53;

ADULT; AGE; APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CRANIOTOMY; FEMALE; GENDER; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STAINING; TUMOR LOCALIZATION;

EID: 0033994817     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012087     Document Type: Article

References (37)

1. Ciric I, Ammirati M, Vick N, Mikhael M: Supratentorial gliomas: Surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 1987;21:21-26.
2. Forsyth PA, Shaw EG, Scheithauer BW, O'Fallon JR, Layton DD, Katzmann J: Supratentorial pilocytic astrocytomas. Cancer 1993;72: 1335-1342.
3. Garcia DM, Fulling KH, Marks JE: The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum. Cancer 1985;55:919-927.
4. Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lcmairc JJ, Plagne R, Rozan R: Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 1994;73: 1937-1945.
5. Kreth FW, Faist M, Rossner R, Volk B, Ostertag C: Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas. Cancer 1996;79:370-379.
6. Krouwer HG, Davis RL, Silver P, Prados M: Gemistocytic astrocytomas: A reappraisal. J Neurosurg 1991;74:399-406.
7. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G: Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15:1294-1301.
8. Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients. J Clin Oncol 1997;15:3129-3140.
9. Lunsford LD, Somaza S, Kondziolka D, Flickinger JC: Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 1995;82:523-529.
10. McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J: Treatment and survival of low-grade astrocytoma in adults -1977-1988. Neurosurgery 1992;31:636-642.
11. Miralbell R, Balart J, Matias G, Molet J, Ariza A. Craven-Bartle J: Radiotherapy for supratentorial low-grade gliomas: Results and prognostic factors with special focus on tumour volume parameters. Radiother Oncol 1993;27:112-116.
12. North CA, North RB, Epstein JA, Piantadosi S, Wharam MD: Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 1990;66:6-14.
13. Picpmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R: Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996; 38:872-878.
14. Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O'Fallon JR, Earle JD, Laws ER Jr, Okazaki H: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853-861.
15. Shibamoto Y, Kitakabu Y, Takahashi M, Yamashita J, Oda Y, Kikuchi H, Abe M: Supratentorial low-grade astrocytoma: Correlation of computed tomography findings with effects of radiation therapy and prognostic variables. Cancer 1993;72:190-195.
16. Soffietti R, ChiÒ A, Giordana MT, Vasario E, Schiffer D: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 1989;24:686-692.
17. Vigliani MC, Sichez N, Poisson M, Delatire JY: A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results, Int J Radiat Oncol 1996;35:527-533.
18. Hsu DW, Louis DN. Efird JT, Hedley-Whyte ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997;56:857-865.
19. Nakamura M, Konishi N, Hiasa Y, Tsunoda S, Fukushima Y, Tsuzuki T, Takemura K, Aoki H, Kobitsu K, Sakaki T: Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. Int J Oncol 1996;8:889-893.
20. Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Inui T, Sakaki T: Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997;80:242-249.
21. Willet CW, Warland G, Cheek R, Coen J, Efrid J, Schellito PC, Compton CC: Proliferating cell nuclear antigen and mitotic activity in rectal cancer: Predictor of response to preoperative irradiation. J Clin Oncol 1994;12:679-682.
22. Symonds H, Krall L, Remington L, SaenzRobles M, Lowe S, Jacks T, Van Dyke T: p53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703-711.
23. Thompson CB: Apoptosis in the pathogencsis and treatment of disease. Science 1995;267: 1456-1462.
24. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-967.
25. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutations does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-3669.
26. Hawkins DS, Deniers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-898.
27. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 1996;15:1-4.
28. Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-5746.
29. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
30. Aoki H, Ohnishi K, Wang X, Takahashi A, Ohnishi T, Nakamura M, Sakaki T: p53-independent WAF1 induction by ACNU in human glioblastoma cells. Mol Carcinog 1998;21:171-176.
31. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846-847.
32. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M: Alterations of RB, p53, p16 (CDKN2), and p15 genes in human astrocytomas. Cancer 1996;78:287-293.
33. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumours of the central nervous system. Berlin, Springer, 1993.
34. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
35. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
36. Fadul C, Wood J, Thaler H, Galicich J, Patterson RH Jr, Posner JB: Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1988;38:1374-1379.
37. Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 1982;12:231-237.